Samsung Biologics Co Ltd (207940) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has a cash flow conversion efficiency ratio of 0.075x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩624.80 Billion ≈ $423.42 Million USD) by net assets (₩8.36 Trillion ≈ $5.67 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Samsung Biologics Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Samsung Biologics Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Samsung Biologics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Samsung Biologics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samsung Biologics Co Ltd ranked by their cash flow conversion efficiency. Explore Samsung Biologics Co Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferguson Plc
NYSE:FERG
|
0.131x |
|
Shanghai Pudong Development Bank Co Ltd
SHG:600000
|
0.109x |
|
Thomson Reuters Corp
TO:TRI
|
0.083x |
|
Banco Santander Brasil SA ADR
NYSE:BSBR
|
0.309x |
|
BASF SE
XETRA:BAS
|
0.014x |
|
Humana Inc
NYSE:HUM
|
-0.022x |
|
AngloGold Ashanti Ltd
JSE:ANG
|
0.133x |
|
CTBC Financial Holding Co Ltd
TW:2891
|
0.246x |
Annual Cash Flow Conversion Efficiency for Samsung Biologics Co Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Samsung Biologics Co Ltd from 2014 to 2025. View 207940 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩7.45 Trillion ≈ $5.05 Billion |
₩2.25 Trillion ≈ $1.52 Billion |
0.302x | +98.26% |
| 2024-12-31 | ₩10.90 Trillion ≈ $7.39 Billion |
₩1.66 Trillion ≈ $1.12 Billion |
0.152x | -10.23% |
| 2023-12-31 | ₩9.83 Trillion ≈ $6.66 Billion |
₩1.67 Trillion ≈ $1.13 Billion |
0.169x | +59.79% |
| 2022-12-31 | ₩8.98 Trillion ≈ $6.09 Billion |
₩953.05 Billion ≈ $645.87 Million |
0.106x | +16.46% |
| 2021-12-31 | ₩4.99 Trillion ≈ $3.38 Billion |
₩454.60 Billion ≈ $308.07 Million |
0.091x | +107.27% |
| 2020-12-31 | ₩4.60 Trillion ≈ $3.12 Billion |
₩202.09 Billion ≈ $136.95 Million |
0.044x | +1784.58% |
| 2019-12-31 | ₩4.35 Trillion ≈ $2.95 Billion |
₩10.15 Billion ≈ $6.88 Million |
0.002x | +129.35% |
| 2018-12-31 | ₩4.16 Trillion ≈ $2.82 Billion |
₩-33.02 Billion ≈ $-22.38 Million |
-0.008x | -121.09% |
| 2017-12-31 | ₩3.98 Trillion ≈ $2.69 Billion |
₩149.82 Billion ≈ $101.53 Million |
0.038x | +345.46% |
| 2016-12-31 | ₩4.08 Trillion ≈ $2.77 Billion |
₩-62.66 Billion ≈ $-42.46 Million |
-0.015x | +83.96% |
| 2015-12-31 | ₩2.77 Trillion ≈ $1.88 Billion |
₩-265.51 Billion ≈ $-179.93 Million |
-0.096x | +44.27% |
| 2014-12-31 | ₩630.73 Billion ≈ $427.44 Million |
₩-108.30 Billion ≈ $-73.39 Million |
-0.172x | -- |
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offe… Read more